Please use this identifier to cite or link to this item: https://ir.swu.ac.th/jspui/handle/123456789/29282
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLeowattana W.
dc.contributor.authorLeowattana P.
dc.contributor.authorLeowattana T.
dc.contributor.otherSrinakharinwirot University
dc.date.accessioned2023-11-15T02:08:14Z-
dc.date.available2023-11-15T02:08:14Z-
dc.date.issued2023
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85151043917&doi=10.3748%2fwjg.v29.i10.1569&partnerID=40&md5=8c62428583c2bd61cbb966e8d33549fb
dc.identifier.urihttps://ir.swu.ac.th/jspui/handle/123456789/29282-
dc.description.abstractSignificant progress has been achieved in the treatment of metastatic colorectal cancer (mCRC) patients during the last 20 years. There are currently numerous treatments available for the first-line treatment of mCRC. Sophisticated molecular technologies have been developed to reveal novel prognostic and predictive biomarkers for CRC. The development of next-generation sequencing and whole-exome sequencing, which are strong new tools for the discovery of predictive molecular biomarkers to facilitate the delivery of customized treatment, has resulted in tremendous breakthroughs in DNA sequencing technology in recent years. The appropriate adjuvant treatments for mCRC patients are determined by the tumor stage, presence of high-risk pathologic characteristics, microsatellite instability status, patient age, and performance status. Chemotherapy, targeted therapy, and immunotherapy are the main systemic treatments for patients with mCRC. Despite the fact that these novel treatment choices have increased overall survival for mCRC, survival remains optimal for individuals with non-metastatic disease. The molecular technologies currently being used to support our ability to practice personalized medicine; the practical aspects of applying molecular biomarkers to regular clinical practice; and the evolution of chemotherapy, targeted therapy, and immunotherapy strategies for the treatment of mCRC in the front-line setting are all reviewed here. ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
dc.publisherBaishideng Publishing Group Inc
dc.subjectBiomarkers
dc.subjectChemotherapy
dc.subjectImmunotherapy
dc.subjectMetastatic colorectal cancer
dc.subjectPersonalized medicine
dc.subjectSystemic treatment
dc.subjectTargeted therapy
dc.titleSystemic treatment for metastatic colorectal cancer
dc.typeReview
dc.rights.holderScopus
dc.identifier.bibliograpycitationWorld Journal of Gastroenterology. Vol 29, No.10 (2023), p.1569-1588
dc.identifier.doi10.3748/wjg.v29.i10.1569
Appears in Collections:Scopus 2023

Files in This Item:
There are no files associated with this item.


Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.